WILL ANTIBIOTIC INDUSTRY RISE UP TO THE CHALLENGE OF TACKLING GROWING ANTIBIOTIC RESISTANCE?

  28 January 2020

Melinta Therapeutics (NASDAQ: MLNT), a commercial-stage pharmaceutical Company, engaged in developing therapeutic options for treatment of bacterial infectious diseases, filed for Chapter 11 bankruptcy in January 2020.  The Company had concerns about its financial prospects and warned the investors that it would be difficult to continue as a going concern. Melinta will now be controlled by Deerfield and receive 100% of the equity issued by the new company, in lieu of the $140 million loan it extended to Melinta. Deerfield will help the Company in its reorganization, which will include lay off of nearly 60 people.

Further reading: Avis & Analytics
Author(s): Avis & Analytics
Smart Innovations  
Back

OUR UNDERWRITERS

Unrestricted financial support by:

Antimicrobial Resistance Fighter Coalition

Evotec

JSS University





Technology Database

Display your AMR Technology, Product and Service

Suppliers and Users of Technologies, Products and Services benefit from CAPI.
CAPI (Continuous AMR Partnering Initiative) unites Suppliers and Users worldwide with the aim to add to the curbing of AMR.

Read more and make your own Technology Page >>
What is going on with AMR?
Stay tuned with remarkable global AMR news and developments!